Precision Medicine in Chinese Patients With Young Onset Diabetes

NCT ID: NCT04049149

Last Updated: 2022-07-20

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: NA
• Total Enrollment: 884 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-01-14
• Study Completion Date: 2024-12-31

Brief Summary

Patients with young onset diabetes (YOD) are one of the most challenging groups of patients due to their long disease duration, complex causes, delayed interventions, psychosocial stress, poor adherence and frequent default. The investigator's previous studies indicate that provision of biogenetic information improved satisfaction, reduced ambiguity and improved self-efficacy in patients with T2D. Provision of personalized information using the web-based Joint Asia Diabetes Evaluation (JADE) Technology with risk stratification and decision support empowers better self care and medical intervention with improved control of risk factors. To further improve the precision of diagnosis for individualizing care, the use of CP, GADA, genetic risk scores (GRS) or rare genetic variants of maturity onset of diabetes (MODY) can help doctors select the most appropriate therapy in a timely manner. While patients with low CP, GADA and high GRS will benefit from early insulin therapy, some MODY variants are associated with good response to insulin-releasing oral drugs (e.g. sulphonylurea) which may spare the use of insulin with reduced patient distress and over-insulinization. By contrast, patients with high CP often due to obesity-associated insulin resistance should undergo intensive lifestyle modification and use of drugs with weight-reducing or neutral effects to avoid weight gain due to excessive dose of insulin.

Detailed Description

Patients with young onset diabetes (YOD) are one of the most challenging groups of patients due to their long disease duration, complex causes, delayed interventions, psychosocial stress, poor adherence and frequent default. The investigator's previous studies indicate that provision of biogenetic information improved satisfaction, reduced ambiguity and improved self-efficacy in patients with T2D. Provision of personalized information using the web-based Joint Asia Diabetes Evaluation (JADE) Technology with risk stratification and decision support empowers better self care and medical intervention with improved control of risk factors. To further improve the precision of diagnosis for individualizing care, the use of CP, GADA, genetic risk scores (GRS) or rare genetic variants of maturity onset of diabetes (MODY) can help doctors select the most appropriate therapy in a timely manner. While patients with low CP, GADA and high GRS will benefit from early insulin therapy, some MODY variants are associated with good response to insulin-releasing oral drugs (e.g. sulphonylurea) which may spare the use of insulin with reduced patient distress and over-insulinization. By contrast, patients with high CP often due to obesity-associated insulin resistance should undergo intensive lifestyle modification and use of drugs with weight-reducing or neutral effects to avoid weight gain due to excessive dose of insulin.

PART 1:

Objective: To characterize Chinese patients diabetes classified by fasting CP and GADA positivity and their prognostic significance.

Methods: Fasting CP levels and GADA in stored biosamples of 4000 patients in the Hong Kong Diabetes Register (HKDR) followed up since 1995.

PART 2:

Objective: To uncover genetic variants/sequences associated with familial YOD. Methods: Whole genome sequencing (WGS) in stored DNA of 100-120 sibpairs of YOD after 13 years of follow-up for imputation with exome data of case-control cohort of YOD and genome wide association studies (GWAS) data of 200 YOD families and 6000 T2D patients.

PART 3:

Objectives: To examine the impacts of precision medicine augmented by information technology and biogenetic markers (JADEPRISM) on attainment of cardiometabolic targets at 1 year and clinical outcomes at 3 year (n=440), compared with JADE-augmented care (n=440) in YOD.

Deliverables A catalogue of biogenetic markers to guide precision medicine augmented by the JADE-Technology to optimize clinical outcomes in YOD.

Conditions

Type 2 Diabetes

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: HEALTH_SERVICES_RESEARCH
• Blinding Strategy: NONE

Study Groups

JADE-PRISM group

Only applicable in part 3 which is a randomized controlled trial. Part 1 and part 2 are the prospective cohort studies.

Group Type: OTHER

Biogenetic explanation and endocrinologist intensive managment

Intervention Type: OTHER

• JADE report and JADE APP
• Biogenetic explanation
• First-year intensive management by endocrinologists
• Follow up by their usual care doctors for continue treatment regimen maintenance.
• Yearly DM nurses follow up for blood taking and questionnaires

JADE group

Only applicable in part 3 which is a randomized controlled trial. Part 1 and part 2 are the prospective cohort studies.

Group Type: OTHER

Usual care management

Intervention Type: OTHER

• JADE report and JADE APP
• Attend their usual care clinic for ongoing treatment
• Yearly DM nurses follow up for blood taking and questionnaires

Interventions

Biogenetic explanation and endocrinologist intensive managment

• JADE report and JADE APP
• Biogenetic explanation
• First-year intensive management by endocrinologists
• Follow up by their usual care doctors for continue treatment regimen maintenance.
• Yearly DM nurses follow up for blood taking and questionnaires

Intervention Type: OTHER

Usual care management

• JADE report and JADE APP
• Attend their usual care clinic for ongoing treatment
• Yearly DM nurses follow up for blood taking and questionnaires

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

Part 1: Prospective cohort of Chinese with type 2 diabetes

Between 1995 and December 2004, 10,129 patients were assessed using structured protocol to esetablish the HKDR and of them, we have measured GADA and CP in 1400 patients with YOD. In this study, we shall measure CP and GADA in 4000 subjects from the HKDR with available GWAS data irrespective of their age of diagnosis. These samples were linked to our various databases by a unique identification code which will enable us to track the clinical outcomes including development of complications.

Part 2: Family-based cohort of first-degree relatives of diabetic probands

We shall utilize the resource of the HKDFS and control subjects to discover novel genetic variants of YOD. Subjects will be selected based on their status with or without diabetes. In 2012-2013, we ascertained the glycemic status of 365 siblings in the HKDFS and 452 participants of the community-based LKS cohort (aged 18-55 years) without diabetes at baseline (1998-2002).

In this cohort, 167 participants (53.7%) with a family history of YOD, 68 participants (30.1%) with a family history of late onset diabetes and 40 (14.4%) participants without family history of diabetes developed diabetes. Amongst the 313 siblings with family history of YOD, 167 had diabetes at baseline or developed diabetes during follow up and 146 did not develop diabetes after 13 years giving 100-120 sibpairs for linkage analysis. These sequence data will be imputed with 500 YOD patients and 500 control subjects with exome data as well as 6000 patients in the HKDR with GWAS data for analysis for validation purpose.

Part 3: RCT (PRISM)

• Non-type 1 diabetes (T1D)
• Chinese ethnicity
• Age between 18-50 years inclusive
• Age at diabetes diagnosis 40 years
• Able to understand study requirements and voluntarily agree to participate by providing written informed consent

Exclusion Criteria

Part 1/2:

Subjects in the HKDR, HKFDS and LKS cohorts without or insuffiicent amount of biosamples for assays or sequencing.

Part 3:

• T1D, defined by presentation with diabetic ketoacidosis or insulin requirement within 6 months of diagnosis.
• Reduced life expectancy due to terminal illness or otherwise deemed not appropriate per discretion of the investigator

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 50 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Chinese University of Hong Kong

OTHER

Sponsor Role: lead

Responsible Party

Juliana Chan

Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Juliana Chan, MD

Role: PRINCIPAL_INVESTIGATOR

Chinese University of Hong Kong

Locations

The Chinese University of Hong Kong

Shatin, , Hong Kong

Countries

Hong Kong

References

O CK, Fan YN, Fan B, Lim C, Lau ESH, Tsoi STF, Wan R, Lai WY, Poon EW, Ho J, Ho CCY, Fung C, Lee EK, Wong SY, Wang M, Ozaki R, Cheung E, Ma RCW, Chow E, Kong APS, Luk A, Chan JCN. Precision Medicine to Redefine Insulin Secretion and Monogenic Diabetes-Randomized Controlled Trial (PRISM-RCT) in Chinese patients with young-onset diabetes: design, methods and baseline characteristics. BMJ Open Diabetes Res Care. 2024 Jun 19;12(3):e004120. doi: 10.1136/bmjdrc-2024-004120.

Reference Type: DERIVED

PMID: 38901858 (View on PubMed)

Other Identifiers

CRE-2019.080

Identifier Type: -

Identifier Source: org_study_id